Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism

Contraception

Volumn 88, Issue 3, 2013, Pages 364-368

  De Leo, Vincenzo ^a   Fruzzetti, Franca ^b   Musacchio, Maria Concetta ^a   Scolaro, Valeria ^a   Di Sabatino, Alessandra ^a   Morgante, Giuseppe ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Carbohydrate metabolism; Contraception; Dienogest; Estradiol valerate; Insulin sensitivity

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; GLUCOSE; INSULIN;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; BODY MASS; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE;

CARBOHYDRATE METABOLISM; CONTRACEPTION; DIENOGEST; ESTRADIOL VALERATE; INSULIN SENSITIVITY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; ITALY; NANDROLONE; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84883464079     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.09.003     Document Type: Article

References (25)

1. C.L. Shufelt, and C.N. Bairey Merz Contraceptive hormone use and cardiovascular disease J Am Coll Cardiol 53 2009 221 231
2. T.M. Farley, O. Meirik, and J. Collins Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks Hum Reprod Update 5 1999 721 735
3. I.F. Godsland The influence of female sex steroids on glucose metabolism and insulin action J Intern Med Suppl 738 1996 1 60
4. D. Crook, and I. Godsland Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism Contraception 57 1998 189 201
5. A. Cagnacci, S. Ferrari, A. Tirelli, R. Zanin, and A. Volpe Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial Contraception 79 2009 111 116
6. F. Fruzzetti, V. Lazzarini, and C. Ricci Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention Contraception 76 2007 190 194
7. R.B. Machado, F. Tachotti, G. Cavenague, and E. Maia Effects of two different oral contraceptives on total body water: a randomized study Contraception 73 2006 344 347
8. L.M. Lopez, D.A. Grimes, and K.F. Schulz Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus Cochrane Database Syst Rev 4 2009 CD006133
9. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord; Published, online 03-05-2011.
10. G. Benagiano, C. Bastianelli, and M. Farris Hormonal contraception: present and future Drugs Today 44 2008 905 923
11. J.T. Jensen Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest Expert Opin Pharmacother 11 2010 1147 1157
12. A.L. Eilertsen, E. Hoibraaten, and I. Os The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis Maturitas 52 2005 111 118
13. Hoy SM, Scott LJ, Estradiol valerate/dienogest in oral contraception. Drugs 2009; 20;69:1635-46. Review.
14. Parke S, Nahum G, Mellinger U, Junge W. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol 2008;111 (4 Suppl)12:3.
15. M. Oettel, S. Bervoas-Martin, and W. Elger A 19-norprogestin without a 17a-ethinyl group I: dienogest from a pharmacokinetic point of view Drugs Today 31 1995 499 516
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil Steril 81 2004 19 25
17. V. De Leo, A. la Marca, and F. Petraglia Insulin-lowering agents in the management of polycystic ovary syndrome Endocr Rev 24 2003 633 667
18. E. Diamanti-Kandarakis, J.P. Baillargeon, M.J. Iuorno, D.J. Jakubowicz, and J.E. Nestler A modern medical quandary: polycystic ovary syndrome, insulin resistance and oral contraceptive pills J Clin Endocrinol Metab 88 2003 1927 1932
19. S. Nader, and E. Diamanti-Kandarakis Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis Hum Reprod 22 2007 317 322
20. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495
21. W.N. Spellacy, W.C. Buhi, and S.A. Birk Effect of estrogen treatment for one year on carbohydrate and lipid metabolism in women with normal and abnormal glucose tolerance test results. Glucose, insulin, growth hormone, triglycerides, and Premarin Am J Obstet Gynecol 131 1978 87 90
22. W.N. Spellacy, W.C. Buhi, and S.A. Birk The effects of two years of mestranol treatment on carbohydrate metabolism Metabolism 31 1982 1006 1008
23. I.F. Godsland, C. Walton, C. Felton, A. Proudler, A. Patel, and V. Wynn Insulin resistance, secretion, and metabolism in users of oral contraceptives J Clin Endocrinol Metab 74 1992 64 70
24. T. Kojima, S.R. Lindheim, D.M. Duffy, M.A. Vijod, F.Z. Stanczyk, and R.A. Lobo Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives Am J Obstet Gynecol 169 1993 1540 1544
25. M. Oettel, H. Breitbarth, and W. Elger The pharmacological profile of dienogest Eur J Contracept Reprod Health Care 4 Suppl. 1 1999 2 13